Stable formulation containing fumagillin and propylene glycol dicaprate/dicaprylate for the treatment of intestinal infections

摘要

A stable formulation containing fumagillin (I) and propylene glycol dicaprate/dicaprylate. (I) (mono (4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-y l)2,4,6,8-decatetraenedioate) has the following formula: The propylene glycol dicaprate/dicaprylate used is commercially available as propylene glycol dicaprylcaprate under the name Labrafac PG (RTM). Preferably the formulations contain 0.2 - 15 %, especially 8 - 10 % by weight of (I). The formulations may further contain a thixotropic agent, such as colloidal silica, and are formulated as capsules, gels, or syrup for drinking.